Labels

Sunday, December 07, 2008

NEJM -- Efficacy and Safety of Corticosteroids for Persistent Acute Respiratory Distress Syndrome

NEJM -- Efficacy and Safety of Corticosteroids for Persistent Acute Respiratory Distress Syndrome
  • randomly assigned 180 patients with ARDS of at least seven days
  • double-blind (receive either methylprednisolone or placebo)
  • study compared the effect of corticosteroids with placebo in the management of late-phase (greater than seven days) ARDS.
  • The primary endpoint was mortality at 60 days. (significantly increased 60- and 180-day mortality rates among patients enrolled at least 14 days after the onset of ARDS)
  • Secondary endpoints included ventilator-free days and organ failure-free day.(Methylprednisolone increased the number of ventilator-free and shock-free days during the first 28 days)